Lacosamide Fresenius Kabi (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, stabilizing hyperexcitable neuronal membranes and reducing the spread of epileptic discharges without affecting normal rapid channel activity.

The appropriate dose of lacosamide is determined by the prescribing clinician based on the patient’s clinical condition, age, renal function, and response to therapy. Specific dosing regimens are not provided here.

Safety data for lacosamide in pregnancy and lactation are limited. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and decisions should be made in consultation with a healthcare professional.

Enquiries can be submitted on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Lacosamide offers a distinct mechanism by enhancing slow sodium‑channel inactivation, which can be beneficial for patients who have not achieved adequate control with other antiepileptics that act on different pathways, such as sodium‑channel blockers or GABA‑enhancers.

Lacosamide Fresenius Kabi should be stored at ambient temperature, protected from moisture and light, and kept in its original packaging until use. Follow any additional handling instructions provided by the manufacturer.

Lacosamide is administered intravenously by a healthcare professional. The infusion rate and duration are determined by the prescriber and should follow established clinical guidelines.

Serious risks include cardiac arrhythmias such as atrioventricular block, severe skin reactions like Stevens‑Johnson syndrome, and respiratory depression. Patients should be monitored for these events, especially during initiation and dose adjustments.

Lacosamide is contraindicated in patients with known hypersensitivity to the drug or its components, and it should be used with caution in individuals with significant cardiac conduction disorders, severe renal or hepatic impairment, or those taking interacting medications.